POU domain factors are transcriptional regulators characterized by a highly conserved DNA-binding domain referred to as the POU domain. The structure of the POU domain has been solved, facilitating the understanding of how these proteins bind to DNA and regulate transcription via complex protein-protein interactions. Several members of the POU domain family have been implicated in the control of development and function of the neuroendocrine system. Such roles have been most clearly established for Pit-1, which is required for formation of somatotropes, lactotropes, and thyrotropes in the anterior pituitary gland, and for Brn-2, which is critical for formation of magnocellular and parvocellular neurons in the paraventricular and supraoptic nuclei of the hypothalamus. While genetic evidence is lacking, molecular biology experiments have implicated several other POU factors in the regulation of gene expression in the hypothalamus and pituitary gland. Pit-1 mutations in humans cause combined pituitary hormone deficiency similar to that found in mice deleted for the Pit-1 gene, providing a striking example of how basic developmental biology studies have provided important insights into human disease. (Endocrine Reviews 22: 2001) 
T HE ACRONYM POU (pronounced pow) is derived from
the names of three mammalian transcription factors, the pituitary-specific Pit-1 (1, 2), the octamer-binding proteins Oct-1 (3) and Oct-2 (4 -7), and the neural Unc-86 from Caenorhabditis elegans (8) . These initial members of the POU gene family, as well as subsequently discovered members, are characterized by a unique bipartite DNA-binding domain referred to as the POU domain (9) . This domain is composed of a variant homeodomain (POU-H), which is linked via a nonconserved linker to another conserved domain referred to as the POU-specific (POU-S) domain. Both subdomains contain helix-turn-helix motifs that directly associate with the two components of bipartite DNA-binding sites (Fig. 1) .
While highly homologous in the POU domain, the genes expressing the various POU domain factors are distributed on several different chromosomes, not clustered like the Hox genes (10 -19) . POU domain genes have been described in organisms as divergent as C. elegans (20) , Drosophila (21) (22) (23) , Xenopus (24) , zebrafish (25, 26) , and humans, but have not yet been identified in plants or fungi. In all species these genes seem to carry out essential functions for organ development and cellular differentiation.
Although some general conclusions can be reached about POU domain factors, more importantly the various members serve a wide variety of functions during development. In fact, it is reasonable to predict that an individual POU factor may play multiple distinct roles in those organs in which it is expressed during development and in the adult. There is evidence for the role of POU domain factors in inhibition and promotion of cell proliferation and determination of cell lineages, as well as in regulation of cell migration, survival, and terminal differentiation. Because of their overlapping expression patterns and similar DNA-binding preferences, POU factors coexpressed in a single organ may be functionally redundant. In addition to a role in early and late development, members of this family play roles in physiological regulation of gene expression in the adult. While POU domain genes are expressed in all organ systems, this review focuses on the role of POU domain factors in the neuroendocrine system with special emphasis on the hypothalamopituitary axis.
A great deal of knowledge has accumulated about the biological function of POU domain factors since their initial identification in 1988. In addition to insightful in vitro experiments, progress in this field has been greatly facilitated by the ability to create targeted mutations of POU domain genes in the mouse. These studies, as well as the discovery of human disease mutations involving the POU domain factor Pit-1, have established a crucial role for POU domain factors in neuroendocrine development and function.
The 15 known mammalian POU domain genes have been classified into six different groups based on homology in the POU domain region, including the nonconserved linker region ( Table 1 ). The class I POU factor, Pit-1 (GHF-1), is required for the generation and maintenance of three different cell types in the anterior pituitary gland of humans and other mammals (1, 2, 27) . Expression analyses and in vitro biochemical/molecular biology experiments have implicated the octamer-binding proteins Oct-1 and Oct-2, which belong to class II POU domain factors, in neuroendocrine function and development (28 -31) . The third class II factor, Skn-1a, is selectively expressed in epidermis and has no role in the neuroendocrine system (32) (33) (34) (35) . The class III POU domain subgroup consists of four closely related factors, Brn-1, Brn-2, Brn-4, and Tst-1/Oct-6/SCIP, which are all encoded by intronless genes (36) . For members of this subgroup, a role in neuroendocrine development has been most clearly established for Brn-2, which is required for the formation of hypothalamic nuclei and the posterior pituitary gland (37, 38) . The other class III POU factors may also play a crucial role in neuroendocrine function and development. Brn-3 and two other members of the class IV POU factors have been shown to be important for various aspects of sensory development, but have no known roles in the neuroendocrine system and will not be further discussed in this review (39 -48) . The class V POU factor Oct-3 (Oct-4) is expressed in germ cells, embryonic stem cells, and in early neurogenesis where its down-regulation may be crucial for proper neural formation (49 -53). Sprm-1, the second class V factor, is selectively expressed in spermatocytes and has no role in the neuroendocrine system (54, 55). The class VI POU factor Brn-5 is widely distributed and highly expressed in hypothalamic regions (56 -58). The other class VI member, retina-derived POU-domain factor-1 (RPF-1), is expressed in the retina, the medial habenula, and in dispersed populations of neurons in the dorsal hypothalamus (59).
In addition to reviewing the demonstrated or proposed roles for POU domain factors in the neuroendocrine system, we will summarize aspects of the basic molecular biology of POU factors. Extensive investigations into the biochemistry and molecular biology of POU domain factors have given insights into structure-function aspects such as DNA binding, protein-protein interactions, and mechanisms of transcriptional regulation. While many of these studies involve the action of POU domain factors outside the neuroendocrine system, they are informative and likely to provide leads regarding the mechanisms of action for POU domain factors in the neuroendocrine system.
FIG. 1.
The three-dimensional structure of the Pit-1 POU domain bound to DNA compared with the Oct-1 POU domain bound to an octamer site. Pit-1 binds as a dimer to a palindromic PRLrelated DNA site with the POU-S and POU-H domains of each monomer binding to the same side of DNA (left panel). The third helix of both subdomains makes major groove contacts. For comparison, the schematic on the right represents the different organization of Oct-1 bound to an octamer site where the two subdomains bind on the opposite sites of DNA and the Oct-1 POU-S domain (shown in yellow) has a flipped orientation compared with the Pit-1 POU-S domain (shown in pink). 
II. Structure and Transcriptional Function of POU Domain Factors

A. DNA-binding sites for POU domain factors
While POU domain factors exhibit a surprising flexibility in DNA binding (60, 61), a general rule has emerged suggesting that high-affinity binding sites are often bipartite with each "half-site" contacting either the POU-S or the POU-H domain ( Fig. 1) (62, 63) . This principle has been elegantly demonstrated for the interaction of Oct-1 with an octamer site (ATGCAAAT) where the POU-S domain and the POU-H domains associate with the ATGC-and AAATparts, respectively (64 -66). The spacing and orientation between the two halves of a binding element can vary, and the ability of different POU domain factors to recognize such sites depends in part on the length, sequence, and flexibility of the linker tethering the POU-S and POU-H domains (63, 67). In addition, there is evidence that diversity in the POU DNA binding may stem, in part, from amino acid-base interactions that are more flexible than those observed for classical homeodomains (62).
Often, high-affinity binding sites for POU factors are flanked by lower affinity binding sites that are capable of promoting cooperative DNA binding of POU factor dimers. These "second" sites are usually highly diverged from highaffinity binding sites and may contain isolated A/T-rich regions or the POU-S recognition sequence ATG (CAT on the opposite strand). In this section, we will first review the DNA binding characteristics of different POU domain factors, and then summarize the main conclusions from the collection of studies on this issue.
DNA binding sites for the class I factor
Pit-1. Pit-1 was originally identified based on its ability to bind to multiple sites in the regulatory regions of its target genes GH and PRL (1, 2) . Similar Pit-1 binding sites have been described in the regulatory regions of several other pituitary-expressed genes that are likely targets of Pit-1. These include the Pit-1 gene itself (68 -70), the TSH␤ gene (71-73), the rat and human GHRH receptor gene-regulatory regions (74, 75), the rat somatostatin receptor 1 gene-regulatory region (76, 77), and the human TRH receptor gene-regulatory region (78). These sites, which vary widely around the consensus sequence ATGNATA(A/T)(A/T)(A/T), tend to be found in multiples in Pit-1 target genes ( Table 2) . On most sites, Pit-1 appears to bind as a homodimer with one Pit-1 molecule contacting the high-affinity octamer-related sequence, ATGNATA, and the second molecule binding cooperatively to the 3Ј located lower affinity A/T-rich region (79 -81). On some sites Pit-1 can bind as a heterodimer with the POU domain factor Oct-1, and on yet other sites it binds as a monomer (82).
While Pit-1 also binds to the classical octamer site, it does so with lower affinity than to natural sites, and at least in one A  23  0  0  14  23  5  19  13  13  4  T  1  2 5  1  4  2  2 0  5  9  8  1 5  G  0  0  2 4  3  0  0  1  0  4  1  C  1  0  0  4  0  0  0  3  0  4  A  T  G  N  A  T  A  A  A  A  T  T These include the B cell-specific immunoglobin genes (83), the ubiquitously expressed small nuclear (sn)RNA genes (84, 85), the cell cycle-specific histone H2B genes (86) , and a host of other widely and selectively expressed genes (Table 3) . Early studies attempting to identify the transcription factors binding to octamer elements led to the isolation of Oct-1 and Oct-2 as the major components of octamer-binding activity in eukaryotic cells. Review of the literature indicates that the Oct-1 POU domain has a strong preference for the core element, ATGCAAAT, but clearly several variants of the core element are compatible with high-affinity DNA binding ( Table 3 ). Experiments have also indicated that the bases flanking the core octamer provide additional binding specificity (60). Two studies using random DNA-binding selection methods found that Oct-1 can bind to several different DNA sites with high affinity (61, 65), consistent with previously described broad binding specificity for Oct-1 (60). Yet, when the binding sites were aligned, both groups identified an octamer consensus sequence with position 1 (A) and 7 (A) nearly invariant in sites that bear resemblance to octamer sites (65). Both groups found that a "T" in position 1 was common and that a common octamer variant was a "T" instead of an "A" in position 5 (61, 65). Review of the literature describing Oct-1/2 binding sites in gene-regulatory regions of diverse genes also shows a high frequency of octamer-like sequences (Table 3) . It is striking that alignment of these sites results in a consensus sequence remarkably similar to that identified in the two random site selection studies (Table 3) . However, this approach is unlikely to give a true representation of the type of sites found in generegulatory regions because in their studies, investigators are much more likely to identify and report on the well known octamer site rather than more divergent sites.
Oct-1 can also bind to a distinct site, TAATGARAT (R is a purine), found in the herpes simplex virus immediate early (HSV IE) promoters (87, 88) . The affinity of Oct-1 alone for this site is much lower than for that of the octamer element (64), but in contrast to the classical octamer site, this site can promote the formation of a complex of Oct-1 and VP16, which is required for viral transcription (Fig. 2) . The critical feature of this site is the 3Ј-GARAT motif, which is necessary A  8  44  2  0  5  39  42  42  6  11  T  22  1  44  2  11  5  3  4  35  14  G  5  1  0  4 4  0  1  1  0  1  8  C  1 0  0  0  0  3 0  1  0  0  4  1 3  t  A  T  G  C  A  A  A  T  N for the recruitment of VP16, possibly by a mechanism involving the recognition of specific conformations of Oct-1 (62, 89) or direct nucleotide recognition (90) . On this site, the POU-S domain is located on the opposite side of the POU-H domain as compared with Oct-1 bound to a classical octamer site (62).
In addition, Oct-1 can bind to the heptamer element CT-CATGA found next to the octamer site in immunoglobin heavy chain promoters (91) (92) (93) . While divergent from the octamer site, both Oct-1 and Oct-2 can recognize this site, albeit with lower affinity. However, when Oct-1 or Oct-2 occupies the adjacent octamer site, binding to the heptamer site is strongly enhanced (91) (92) (93) . Cooperative binding to the heptamer element occurs when the spacing between the two elements is either 2 or 14 bp, suggesting that the coordinated binding is caused by protein-protein interactions (91) . This cooperative binding to the heptamer site contributes to transactivation by Oct-1 and Oct-2 (91, 93) .
Several divergent sites capable of binding Oct-1 have been identified in diverse genes, including the GnRH gene-regulatory region (28, 29) (Table 3 ). An unusual binding site has been described in the human interleukin 5 (IL-5) promoter. In this site, inverted POU-S binding sites seem to flank two POU-H domain binding sites (94, 95 ). Yet other sites are similar to the TAATGARAT site in that they only contain recognizable POU-H domain binding sites (Table 3 ). The binding specificity of Oct-1 and Oct-2 has been found to be indistinguishable in several studies, and other studies indicate that the third class II POU factor, Skn-1a, has identical binding preferences (35, 96) . These observations suggest that within a POU class, binding preferences tend to be similar.
DNA binding sites for class III factors.
Studies have shown that the class III POU factor Tst-1 binds to and activates octamer site-dependent promoters (97, 98) . Similar to Oct-1, different binding affinities were observed with perfect octamer sites containing distinct flanking sequences, indicating that the flanking sequences are also important determinants of binding affinity for Tst-1 (98) . Tst-1 also binds to five distinct sites in the myelin-specific P0 promoter with a consensus sequence, GA(A/T)T(T/A)ANA, which appears unrelated to the octamer site (99) . The rat GnRH promoter contains three Tst-1 binding sites that appear to conform to the consensus derived from the Tst-1 binding sites in the P0 promoter (100) ( Table 4) . Tst-1 also binds with high affinity to two sites in the JC virus promoter, but only one of the sites confers transcriptional activation. While they are AT-rich, neither site bears any similarity to octamer sites nor the P0 consensus site (101).
FIG. 2. Selective protein-protein interactions involving POU domain factors.
Interactions of POU domain factors with other proteins are influenced both by the amino acid sequence of the POU domain and the sequence and context of the DNA binding site. a, Pit-1 interacts with GATA transcription factors. On promoters containing binding sites for both Pit-1 and GATA, the interaction seems to be cooperative and results in transcriptional activation (left panel). On promoters containing GATA-binding sites, but lacking Pit-1 binding sites, Pit-1 can inhibit GATA binding to DNA and transactivation. b, The cofactors VP16 and OCA-B interact selectively with Oct-1 and Oct-2. VP16 interacts with Oct-1 on TATGARAT DNA sites, with VP16 contacting the GARAT part of the site. This interaction is stabilized by HCF. Oct-1 and VP16 do not interact on a classical octamer site and VP16 is incapable of interacting with the highly related Oct-2, even on TATGARAT sites, indicating that minor differences in the sequence of the POU domain can direct the specificity of protein-protein interactions. In contrast, OCA-B can interact both with Oct-1 and Oct-2. However, this interaction is restricted to sites related to the classical octamer sequence and does not form on TATGARAT sites. 
Brn-2 dimer consensus ATNAT from random sites (103) ATG (C/T) TAAT Brn-2 consensus from random sites (103)
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Brn-2, like Tst-1, can bind to and activate promoters dependent on octamer sites (102) . Rhee et al. (103) employed a random site selection method to determine optimal binding sites for class III POU factors, using Brn-2 as a prototype member. Their study confirmed the ability of class III factors to interact with octamer-like sites, especially those that have an associated heptamer site. In addition, Brn-2 was found to have preference for sites with the consensus ATG(A/ C)AT(A/T) 0 -2 ATTNAT, and on these sites, Brn-2 bound as highly cooperative dimers (103) . Brn-2 binds to a divergent site in the neuronal promoter of the aromatic l-amino acid decarboxylase gene, a sequence that overlaps with a binding site for winged helix/forkhead protein HNF-3 (104) .
Brn-4 DNA binding preferences have also been evaluated by a random site selection method where it was found that the optimal binding site, CAATATGCTAAT, is related to the smaller octamer site, containing a TAAT instead of the AAAT (105) . Thus, the optimal binding sites selected with Brn-2 and Brn-4 are different. It is quite possible that these differences are due to methodological variables rather than bona fide binding differences between these two class III POU factors. Since it is likely that all POU domain factors can bind to DNA in different conformations, it is not surprising that different studies have identified distinct binding sites for class III POU factors. Nonoctamer DNA-binding sites for Brn-4 have been found in the striatal D1 dopamine receptor (106) and proglucagon genes (107) . These sites seem to be most similar to the Tst-1 sites in the P0 and rGnRH promoters (Table 4) .
DNA binding sites for the class V factor Oct-3.
Oct-3 binds with high affinity to octamer sites (108 -110) , but also to so called palindromic Oct factor recognition elements (PORE), which simulate a pair of inverted homeodomain sites separated by 5 bp, ATTTG ϩ5 CAAAT, found in the osteopontin enhancer (Table 5 ). In addition to Oct-3, other Oct factors can bind to this site, either as homodimers or heterodimers (111) . Oct-3 is reported to transactivate more robustly from this element than a classical octamer site (111) .
Oct-3 can also bind to and regulate transcription through an element located in the regulatory region of a gene encoding the embryonic stem cell coactivator UTF1. This element, which is one base different from a classical octamer site (Table 5) , selectively recruits Oct-3 and Sox-2 and is incapable of binding complexes containing Oct-1 and Tst-1 (112). . In experiments using a random site selection method, Brn-5 was found to prefer the binding site GCATAA(T/A)TTAT, which is related to the class IV factor Brn-3 optimal binding site (103) .
DNA binding sites for the class VI factor
In different experiments where Brn-5 site selection was performed with a fixed site, GCAT, followed by eight random nucleotides, an octamer-like sequence was selected: GCATATGATAAT (56). However, it is clear that Brn-5 binds poorly to a classical octamer site (56). Alignment of three high-affinity sites suggested a high-affinity consensus site GCATN 2-3 TAAT (56) ( (Fig. 2) . Seventh, the DNA-binding site can determine the ability of a bound POU factor to recruit associated proteins (Fig. 2) . Finally, target genes that are responsive to POU domain factors frequently have a cluster of POU-binding sites, particularly when the regulatory regions are located at a distance from the promoter.
B. Protein chemistry
The structure of the POU domain has been extensively studied for both Oct-1 and Pit-1, using NMR (113) (114) (115) (116) and crystallographic (66, 117) methods. The similarity in structure between these two POU domains strongly suggests that (Fig. 1) . The two subdomains are structurally independent, and individually they are capable of lowaffinity DNA interactions (64). High-affinity DNA binding, however, requires the intact POU domain, with each subdomain making major groove DNA contacts. The structure of the POU-S domain is characterized by four ␣-helices surrounding a hydrophobic core similar to the helix-turn-helix motif of bacteriophage and 434 repressor, and 434 Cro DNA-binding domains (113, 115) . While somewhat divergent, the POU-H domain, like classic homeodomains, exhibits a helix-turn-helix structure with three ␣-helices (118 -120).
For both the POU-S and POU-H domains, the second and third helix form a helix-turn-helix structure with the third helix docking to DNA in a major groove where amino acids making direct base contacts tend to be conserved among POU domain factors (121, 122) . The two subdomains do not contact each other, and the linker is not visible in the cocrystals, suggesting that it may be unstructured, perhaps providing flexibility to the POU domain ( Fig. 1 ). This flexibility would allow the two subdomains to acquire different orientation and spacing relative to each other, presumably explaining the versatility in DNA sites that can bind POU domain factors, and the variability in surfaces available for interactions with coregulatory proteins (63). This flexibility may depend, in part, on the length of the linker as evidenced by results showing that the Brn-2 POU domain can adopt two different orientations on DNA, while this was not observed with Brn-3, which contains a shorter linker (62, 63). An effect of the linker on DNA binding specificity was also found in experiments comparing binding of chimeric molecules from the Oct-1 and Pit-1 POU domains (123) . It has been shown that optimal binding of Oct-1 to an octamer site requires a minimum linker length between 10 and 14 amino acids (67). Oct-1 molecules with a shorter linker bind DNA only if the POU-S recognition site is inverted in orientation, apparently bringing it closer to the POU-H domain. In addition, mutations of some conserved residues in the Oct-1 linker altered DNA binding, indicating that there are both sequence and length requirements for the function of the linker (67).
An example of the subdomain flexibility is provided by the binding of Oct-1 to the octamer element (ATGCAAAT) where the POU-S domain recognizes the 5Ј-ATGC-part and the POU-H domain recognizes the 3Ј-AAAT-part. On the TAATGARAT site from the herpes simplex virus (HSV) IE promoter, the Oct-1 POU-H domain recognizes the 5Ј-TAAT part, and the POU-S domain recognizes the 3Ј-GARAT part in a flipped orientation as compared with Oct-1 binding to an octamer site (62).
While the primary, secondary, and tertiary structures are similar, crystallographic studies of Oct-1 and Pit-1 on two different DNA sites have shown quite distinct structures as to the relationship between the two POU subdomains (66, 117) (Fig. 1) . The Oct-1 POU domain binds to opposite faces of an octamer DNA-binding site (the histone H2B promoter octamer). In contrast, the Pit-1 subdomains bind to perpendicular faces of a palindromic DNA site (derived from the PRL 1P site), with the POU-S domain exhibiting flipped orientation compared with Oct-1 structure (Fig. 1) . In addition, while Oct-1 binds as a monomer to an octamer site, Pit-1 forms homodimers on the palindromic PRL 1P-related site via interactions between the C terminus of the DNA-recognition helix of the homeodomain and helix ␣1 and the loop between helices ␣3 and ␣4 of the POU-S domain. Most likely, these differences in structure between Oct-1 and Pit-1 are due to the different DNA-binding sites used for cocrystallization, which is supported by data indicating that the Pit-1 POU domain binds as a monomer to a classical octamer site (124) .
It has been shown that POU factors can be modified by phosphorylation. Oct-1 and Pit-1, for example, are phosphorylated on homologous residues in the POU domain, Ser-385 and Thr-220, respectively, and this phosphorylation leads to decreased DNA binding to octamer and GH POU sites (125, 126) . On other sites, such as those found in the TSH␤ and PRL promoters, phosphorylation by protein kinase A or C enhances DNA binding (127, 128) . While cAMPdependent kinase can phosphorylate these sites in vitro, the identities of the relevant kinases operating in vivo are unclear. For Oct-1, this phosphorylation occurs in a cell cycle-specific manner, thus explaining the S phase-specific activation of the histone H2B gene by Oct-1 (86, 125) . Jun kinase (JNK)/stressactivated protein kinase can bind to the activation domain of Brn-5 and phosphorylate its POU domain on sites that are distinct from the aforementioned Oct-1/Pit-1 phosphorylation sites. This phosphorylation leads to increased binding to DNA and enhanced transactivation (129). Finally, it has been demonstrated that Pit-1 can be acetylated by CREB-binding protein (CBP), but the biological significance of this finding remains to be determined (130).
C. Protein-protein interactions
POU domain factors regulate transcription by interacting with other proteins. POU interacting proteins can be classified into four classes: DNA-binding transcriptional activators, coregulators, basal factors, and replication factors (131). A prominent feature of POU factors is their ability to form cooperative homodimers, and even heterodimers with other POU factors, especially when bound to the appropriate DNA site (80, 82, 132) (Fig. 2) . POU factors also have a striking ability to interact with a variety of divergent structural domains in heterologous factors, including other DNA-binding proteins and coregulators that are incapable of independent DNA binding. In this chapter we will review protein-protein interactions involving those POU factors expressed in the neuroendocrine system ( Table 7) . Many of these interactions may not be directly relevant to regulation of gene expression in the hypothalamo-pituitary axis, but the principles derived from these studies are likely to apply to studies of POU domain factors in the neuroendocrine system (Fig. 2 ).
Pit-1 interactions.
a. Interactions with DNA-binding proteins. Pit-1 forms highly cooperative homodimers on the natural binding sites in regulatory regions of the GH, PRL, and TSH␤ genes (80). This Pit-1 homodimerization has been shown in living cells with
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POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEMfluorescence resonance energy transfer microscopy (FRET) (133). Functional experiments indicate that the POU-S domain is important for Pit-1-Pit-1 interactions and that homodimerization is important for efficient transactivation (80). The ability of some natural Pit-1 mutants to inhibit Pit-1 action in a dominant negative fashion further supports the importance of Pit-1 homodimerization in gene activation (see
Pit-1 mutations as a cause of combined pituitary hormone deficiency in humans)
. In addition, Pit-1 can form heterodimers with Oct-1, which results in synergistic transactivation of the PRL promoter (82). Pit-1 can also interact to varying degree with several heterologous DNA-binding proteins which, when bound to the same promoter, often lead to synergistic transactivation. These interacting factors include the nuclear hormone receptors TR (thyroid hormone receptor), RAR (retinoic acid receptor), RXR (retinoid X receptor), ER (estrogen receptor), VDR (vitamin D receptor), and GR (glucocorticoid receptor). Pit-1, for example, interacts strongly with RXR and more weakly with TR and RAR, which may play a role in synergistic regulation of the GH promoter (134 -136). Pit-1 can also interact with ER (137-140) and VDR (141) in synergistic activation of the PRL gene. The human PRL promoter is inhibited by glucocorticoids, mediated by a gene regulatory region containing Pit-1 binding sites but no glucocorticoid response element (GRE). Studies show that GR and Pit-1 can interact in solution and that the inhibition does not require GR to bind to DNA (142).
Pitx1, a bicoid-like homeodomain factor, interacts with the N terminus of Pit-1 (143) and synergistically transactivates the PRL promoter with Pit-1 (144, 145). A direct interaction of Pit-1 with the related Pitx2 removes an inhibitory effect of a 39-amino acid C-terminal sequence of Pitx2, thus promoting DNA binding and transactivation (146). Pit-1 also interacts in solution with the LIM homeodomain protein P-Lim (Lhx3) and acts synergistically with P-Lim to regulate the PRL enhancer/promoter (147).
Synergistic interactions between Ets-1 and Pit-1 may be important in regulation of the PRL promoter. The synergistic gene activation requires direct Pit-1-Ets-1 protein-protein in- Interactions between Pit-1 and the transcription factor GATA-2 are more complex and have distinct features depending on whether both factors bind to DNA (150, 151) ( Fig.  2A) . Pit-1 and GATA-2 can interact in solution (150, 151), and the interaction interface maps to the POU-H domain of Pit-1, specifically the N-terminal basic residues and the surface of the second helix (P26, Q29) (151). In GATA2, the C-terminal DNA-binding zinc finger and an adjacent cluster of basic residues seem to be important. Pit-1 can inhibit binding of GATA-2 to cognate DNA sites on promoters that do not have Pit-1 binding sites, such as the gonadotrope-specific SF-1 promoter (151) ( Fig. 2A ). This seems to be important for generation of the gonadotrope phenotype. In contrast, Pit-1 leads to synergistic activation with GATA-2 on promoters containing adjacent Pit-1 and GATA-2 sites, such as the thyrotrope-specific TSH␤ promoter (150, 151) ( Fig. 2A) . As described later, these interactions may be important for the formation of both thyrotrope and gonadotrope cell types.
b. Interactions with coregulator proteins.
In addition, Pit-1 has been demonstrated to interact with coregulators. The POU domain of Pit-1 interacts with CREB binding protein (CBP) through two cysteine-histidine rich domains (C/H1 and C/H3) (152, 153) (Fig. 3) . Pit-1 can also, via its POU-H domain, interact with the corepressor N-CoR (nuclear receptor and corepressor) (153). As will be described later, these interactions may be important for transactivation and the role of Pit-1 in signal transduction. In solution, the POU domains of Oct-1 and Oct-2 can bind to the DNA-binding domain of GR, including an interface that contains amino acids C500 and L501 (156). Again the POU-H domain of Oct-1 seems to be responsible for the interaction (156). Microinjection experiments in zebrafish embryos suggest that such DNA-independent effects of GR involving interactions with the Oct-1 and Oct-2 POU-H domains are biologically important (157). The GR-Oct-1 interaction can both modulate the transcriptional activity of Oct-1 on certain promoters, like the GnRH promoter as detailed later (158), and the activity of GR on its target genes (138). On the mouse mammary tumor virus (MMTV) promoter, it has been shown that Oct-1 and GR bind in a cooperative fashion and that this leads to a synergistic transcriptional regulation on naked DNA templates in vitro (159). Oct-2 can also bind cooperatively with GR, and this also results in synergistic transcriptional regulation (156, 160). In vivo results indicate that Oct-1 binding to the MMTV promoter is strictly glucocorticoid dependent, consistent with a role for GR in remodeling of chromatin to promote access of other factors to the MMTV promoter, such as nuclear factor 1 (NF-1) and Oct-1 (161, 162).
Oct-1 and
On templates containing GREs and octamer sites, Oct-2A and GR can synergize transcriptionally (156, 163). However, when GR sites are not present, GR strongly inhibits transactivation by Oct-2A, while the reciprocal is not true. This effect does not seem to depend on interference with Oct-2A DNA binding, but more likely is due to competition for rate-limiting coactivator molecules (163). A minimal promoter driven by Oct-1, binding to an octamer element, can also be inhibited by GR in a hormone-dependent manner. This interaction seems to be mediated by a strong solution interaction between GR and Oct-1, resulting in inhibition of Oct-1 DNA-binding (164). This interaction, which seems to involve the POU-H domain of Oct-1, can be inhibited by GR binding to a GRE (156). While the mechanism is unclear, functional analyses indicate that androgen-mediated repres-
A schematic model describing mechanisms of transcriptional regulation by Pit-1. Pit-1, which binds as a dimer to DNA, can associate with the CREB-binding protein (CBP)/p300 complex mediating histone acetylation and gene activation. CBP may also mediate cAMP responses on Pit-1 target genes. Alternatively, Pit-1 may associate with complexes that mediate histone deacetylation and repression of gene expression. Presumably, differential association with these two complexes can determine the transcriptional outcome of Pit-1 binding to a promoter region. In addition, the N terminus of Pit-1 participates in transcriptional activation, perhaps by making direct contacts with the core transcriptional machinery. In addition, several factors, such as the DNA site proteins bound to adjacent DNA sites and modifications of Pit-1 itself, contribute to transcriptional regulation.
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POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEMsion of the dehydroepiandrosterone sulfotransferase gene promoter requires Oct-1 binding to the promoter. Since there seems to be no direct AR binding to this promoter, AR-Oct-1 interactions may be important (165). Oct-1 can interact with several other DNA-binding factors, including Sp1 (166, 167), AP-1 (168 -170), CCAAT/enhancer binding protein-␤ (C/EBP␤) (171), NF-1 (172, 173) , and MEF2 (174) . Oct-1/2 interactions with heterologous DNA-binding proteins can either result in transcriptional synergism, as exemplified by the AP-1/Oct-1 interaction (168 -170), or interference as exemplified by C/EBP␤ inhibition of Oct-1 function (171) .
Interaction of the high mobility group protein HMG2 with the POU domains of Oct-1 and Oct-2 leads to cooperative binding (175) . The related HMG I(Y), a known octamerbinding protein, functions as a coactivator with Oct-2A but not Oct-1 for HLA-DRA transcription. Apparently HMG I(Y) facilitates the binding of both Oct-1 and Oct-2 to octamer sites (176) by a mechanism that involves interactions between HMG I(Y) and the POU domains of Oct-2 and Oct-1. However, synergistic transactivation of the HLA-DT gene is only found with Oct-2 and seems to depend on sequences within the C terminus of Oct-2 (177).
b. Interactions with coregulator proteins.
The B cell-specific coactivator OCA-B (also referred to as OBF-1 and Bob-1), a 256-amino acid, proline-rich protein with no close homologs in the database, interacts specifically with the POU domains of Oct-1 and Oct-2 and is required for B cell-specific activation of immunoglobin genes (178 -183) . By interacting with Oct-1 and Oct-2, OCA-B can be recruited to a subset of octamer sites where it serves a coactivator function for transcription (184) (Fig. 2B) . In part, a strong transactivation domain in the C terminus of OCA-B mediates this effect, while the N terminus contains the domain interacting with POU domains (185) . This interaction is specific for Oct-1 and Oct-2 ( Fig. 2B) and not observed for other POU domain factors such as Oct-3, Oct-6, and Pit-1. The specificity of the interaction of OCA-B with both the POU-S and the POU-H domains is determined by residues in the first helix of the POU-S domain (L6 and E7) and the end of the third POU-H domain helix (K155 and I159) (124, 184) . Other residues in the POU domain, including L53 and N59 in the POU-S domain, have been shown to be important for the Oct-OCA-B interactions. However, these residues are conserved in POU domain factors that do not interact with OCA-B and are thus unlikely to determine the specificity of the interaction.
Immunoglobin promoters are strongly activated by OCA-B, whereas the histone H2B promoter is poorly activated, suggesting that there is some promoter-specific restriction of the ability of OCA-B to transactivate. Further specificity is observed on the immunoglobin promoters because OCA-B only seems to activate on sites in the proximal promoter but not on distally located enhancer sites (124) . In addition, the Oct-1/Oct-2-OCA-B complex can only occur on octamer sites that contain an A in the fifth position of the octamer site, such as found in the classical octamer site (Fig.  2B ). Position ϩ3, ϩ4, and ϩ6 also appear to be important (124, 184) . Apparently, OCA-B makes direct contacts with the DNA backbone in the middle of the octamer site, via its N terminus, in addition to POU domain contacts (186, 187) . It has been proposed that OCA-B clamps the two POU subdomains together and at the same time bridges the DNA within the octamer motif at several positions. According to this model, OCA-B may help organize the conformation and stabilize the DNA binding of the Oct POU domain on DNA (124, 184) . There is also evidence that binding of OCA-B to the Oct-1 POU domain/octamer complex induces a partial folding of OCA-B (186) .
Another extensively studied coregulator is VP16. In human cells infected with the herpes simplex virus (HSV), viral gene expression is initiated with the viral protein VP16, which regulates the HSV immediate-early (IE) genes. VP16 does not bind DNA directly, but is instead recruited to IE promoters by its association with Oct-1 (87, 188 -192) (Fig.  2B) . Another cellular protein, host cell factor (HCF), is required for nuclear import of VP16 (193) and stabilization of the VP16-Oct-1 interaction (194 -197) . After infection, VP16 first forms a complex with HCF, which then promotes its interaction with Oct-1 and binding to the TAATGARAT motif in the HSV IE promoters (Fig. 2B) . The interaction of the Oct-1 POU domain and VP16 is selective and not observed with the highly homologous Oct-2 POU domain (198) (Fig.  2B ). Selective residues, particularly a glutamic acid residue (E22) located on the surface of the second helix of the POU-H domain, are critical for the recognition by VP16 (199, 200) . In the Oct-2 POU-H domain, the analogous residue is an alanine, thus precluding interaction with VP16. In addition, the interaction between Oct-1 and VP16 requires the 3Ј-end GA-RAT of the TAATGARAT motif to be intact for ternary complex formation (89, 90) (Fig. 2B) . VP16 alters gene regulation by Oct-1 in two distinct ways. First, it provides a transactivation domain that is highly active on mRNA promoters where the Oct-1 transactivation domain is inactive, and second, it stabilizes the Oct-1-binding to VP16-responsive elements (184) .
c. Interactions with basal transcription factors. SNAPc (snRNA activating protein complex; also referred to as PTF) is a basal transcription factor, composed of several well defined peptides, that binds to promoter elements called the proximal sequence element (PSEs) in both RNA Pol II and Pol III snRNA promoters (84, 201, 202) . Oct-1 binds to the enhancer or distal sequence elements (DSEs) in snRNA promoters, which leads to cooperative binding with SNAPc via a protein-protein interaction involving the POU-S domain of Oct-1, especially residue E7, and the C-terminal region of SNAP190, a major component of the SNAPc (203) . The result is an enhanced transcriptional activation by Oct-1-mediated recruitment of SNAPc to the PSE of snRNA genes (204) . The carboxy terminus of SNAP190 acts as an inhibitor of SNAPc DNA binding, but the interaction with the Oct-1 POU domain relieves the inhibition and promotes cooperative binding; SNAPc binds with 8-to 10-fold higher affinity when Oct-1 is bound to the DSE (205, 206) .
The POU domains of Oct-1 and Oct-2 have been shown to interact with the TATA binding protein TBP (207) . Since this interaction was in solution and not on DNA, its significance is somewhat unclear. However, this finding is consistent with the observation that Oct-1 and Oct-2 can facilitate is required for the assembly of cyclin-dependent kinase (CDK)-activating kinase (CAK), which is functionally associated with the general transcription factor IIH (TF II H). The interaction between POU domains and MAT1 can target CAK to octamer binding factors and promote their phosphorylation. This interaction may play a role in the recruitment of TF II H to the preinitiation complex (210) .
d. Interactions with replication factors.
Oct-1 is involved in adenovirus replication where it binds to the highly conserved core origin and interacts via its POU domain with one of the three viral proteins required for replication, the precursor terminal protein (pTP) (122, 211, 212) . The interaction seems to involve several regions of the pTP protein (213) . The POU-H domain binds to the pTP-DNA polymerase complex (213) , but more weakly than the intact POU domain. No binding is observed with the POU-S domain alone (214) . Presumably, this interaction facilitates the recruitment of the pTP-DNA polymerase complex to the origin of replication. The stimulation of adenovirus DNA replication seems to depend on a property of the POU domain that is common to many POU domains because other POU domain factors, including Pit-1 and Tst-1, can also stimulate DNA replication (215).
Class III POU interactions.
a. Interactions with DNA-binding proteins. Based on farWestern and mammalian two-hybrid experiments, all class III POU domain factors can interact with each other via the POU homeodomain (216) . Consistent with this observation, Brn-2 exhibits highly cooperative homodimerization on a consensus nonoctamer binding site (103) .
Sox/HMG proteins are transcription factors that contain Sry boxes that mediate binding to the minor groove of DNA. Such factors may frequently interact with POU domain factors that bind to the major groove of DNA. Tst-1 (Oct-6) can interact with HMG I(Y) in solution, which facilitates Tst-1-binding to an AT-rich site in the JC viral regulatory region (217) . Tst-1 can also interact with the related HMG2 (218). Both Tst-1 and Brn-1 can cooperate with different Sox proteins in transcriptional activation. Specifically, Brn-1 can synergize with Sox-11 when both proteins are bound to adjacent elements; the synergism depends on the transactivation domains in both proteins. Such POU-Sox interactions may be important for a combinatorial code required for cell-specific transcriptional activation (219, 220) .
b. Interactions with coregulator proteins. Tst-1 can interact with the large T antigen from the human papovavirus JC virus, and this interaction seems to lead to transcriptional activation on the early and late promoters from the JC virus (101, 221, 222) . The amino-terminal 82 residues of the large T antigen and the POU domain of Tst-1 mediate this interaction, but for a functional effect on transcription, the Nterminal transactivation of Tst-1 is also required. This functional effect is specific for Tst-1, because while Brn-1 is also capable of interacting with large T antigen, this interaction is not transcriptionally productive, apparently because of differences in the transactivation domains of Brn-1 and Tst-1 (223).
Oct-3 interactions.
a. Interactions with DNA-binding proteins. Oct-3 can interact with the HMG-box protein Sox2 (224) , and these two factors have been implicated in synergistic regulation of the fibroblast growth factor 4 (FGF-4) gene (49) and the embryonic stem cell coactivator gene UTF-1 (112) . The synergism between Oct-3 and Sox2 on the FGF-4 promoter seems to be due to cooperative binding, which can be disrupted by increasing the distance between the two binding sites (109) . In contrast, Sox2 functionally antagonizes Oct-3 on the ostepontin generegulatory region where its binding site is adjacent to that of Oct-3 (111). Oct-3 and Sox2 interact directly in solution, with the interaction interface being the POU domain and the Sox2 HMG domain (109) .
b. Interactions with co-regulator proteins.
In embryonic stem cells Oct-3 transactivation is independent of the distance of the octamer site from the promoter, but in differentiated cells, Oct-3 transactivation from a distance seems to require stem cell-specific coactivators that bridge the remotely bound Oct-3 to the basal transcriptional machinery (225) . While these factors remain to be identified, it is known that transactivation by Oct-3 is strongly stimulated by E1A in 293 and HeLa cells and depends on both the intact POU domain and the transactivation domain of Oct-3. This effect is specific because it is not found with Oct-1 and minimally with Oct-2. Direct binding of Oct-3 to E1A was also demonstrated (225) . The Oct-3 POU domain can associate with two distinct domains on the E1A protein, CR1 and CR2, and it can also associate with the HPV E7 protein (226) . These data suggest that viral oncoproteins have characteristics that mimic a stem cell-specific activity (226).
Conclusions.
From studies on the protein-protein interaction characteristics of POU domain factors several general conclusions can be drawn. First, most factors that interact with POU domain proteins have been found to interact with the POU domain rather than other parts of the proteins. This finding may be due, in part, to technical difficulties in identifying factors that interact with the transactivation domains outside the POU domain. However, these results indicate that the POU domain is not only a DNA-binding domain but also an important interface for regulatory proteins. Second, POU domain factors seem fairly promiscuous as to their ability to interact and synergize with diverse DNA-binding proteins bound to the same promoter. Most POU domain factors have been shown to interact in such a way with nuclear hormone receptors and HMG proteins. Third, while the POU domain is highly conserved, most POU domain interactions with coregulators are remarkably selective; apparently proteins are able to discern small differences in POU domain sequence (Fig. 2B) . Thus, the E1A protein interacts POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEMstrongly with Oct-3 but not Oct-1 or Oct-2. VP16 interacts strongly with Oct-1 but not Oct-2, Oct-3, or Tst-1 (Fig. 2B) . OCA-B interacts selectively with Oct-1 and Oct-2, but not with Oct-3 or Tst-1 (Fig. 2B) . This selectivity for proteinprotein interactions by POU domains is in stark contrast to the lack of selectivity in DNA-binding preferences. Fourth, the association of a coactivator with a POU domain factor may be stabilized by a simultaneous direct interaction of the coactivator with DNA, such as that found with Oct-1/2 and OCA-B (Fig. 2B) . Fifth, some POU factor-coactivator complexes can only form on selective DNA sites, perhaps in part due to direct DNA contacts of coactivators or due to DNAinduced conformational changes of the POU domain as has been described with OCA-B/Oct-1 and VP16/Oct-1 interactions (Fig. 2B) . For example, the Oct-1/2-OCA-B interaction requires an "A" in position 5 of an octamer site (ATG-CAAAT) (184) , and the Oct-1-VP16 interaction requires the GARAT part of a TAATGARAT site for ternary complex formation (90) . Sixth, additional functional specificity is provided by sequences outside the POU domain, such that two distinct POU domain factors may be capable of physical interaction with a coregulator, but only one of the interactions will result in transcriptional activation, apparently because of specific sequences in the transactivation domain. Finally, while some protein-protein interactions involve only one of the subdomains of the POU domain, e.g., the interactions of VP16 with the POU-H domain and SNAPc with the POU-S domain, others such as OCA-B interact simultaneously with the POU-S and the POU-H domains.
D. Mechanisms of transactivation
1. Transactivation domains. While the N-and C-terminal domains in POU domain factors are thought to act as transactivation domains, little is known about their structures. These domains, which frequently contain polymeric amino acid stretches, are poorly conserved between different POU domain factors, consistent with the idea that they confer specificity to the action of different factors, often binding to the same DNA element. The N terminus is serine/threonine rich in Pit-1, alanine/glycine rich in Tst-1, proline rich in Oct-3, and glutamine rich in Brn-2. The N-and C-terminal transactivation domains of Oct-2 have been most extensively characterized (227) (228) (229) (230) . The N terminus contains an 18-amino acid glutamine-rich motif, and the C terminus contains a proline-rich domain (231) . The function of these motifs is enhanced when they are combined or reiterated independently (229, 232) , suggesting that they have a modular structure. The Oct-1 transactivation domain appears to be fairly specific for snRNA promoters and has less effect on mRNA transcription, in contrast to the Oct-2 transactivation domains that are active on mRNA promoters (184, 228) . Studies on Oct-3 suggest that transactivation domains may work in a cell-specific manner (233) . The N-terminal sequence of Oct-3 fused to the GAL4 DNA-binding domain can transactivate in all cell types tested, whereas the C-terminal sequence shows cell-type specificity in the same assay. This cell type specificity of the C-terminal domain seems to be imposed by the Oct-3 POU domain because it functioned in all cell types tested when the C terminus was fused to Pit-1 POU domain. It is further possible that the transactivation specificity is regulated by phosphorylation as the variation in transactivating ability of the C-terminal domain correlates with differences in the phosphorylation status of Oct-3.
Studies on Pit-1 have defined additional specificity conferred by the N-terminal transactivation domain (234) . Thus, synergistic activation by Pit-1 and the estrogen receptor on a PRL reporter construct requires an N-terminal 25-amino acid domain of Pit-1 that is not required for analogous synergism on the GH promoter. This synergy, which depends on two of three tyrosine residues, spaced by six amino acids, is preferentially used on sites where Pit-1 binds as a monomer instead of a dimer. These data suggest that the DNA-binding site, dictating whether Pit-1 binds in dimeric or monomeric form, can alter the segment of the N terminus used as a synergy domain.
The N terminus of Brn-2 contains a glutamine-rich region that is mainly encoded by CAG residues (36) . Similar nucleotide triplets that can be expanded are found in disease genes causing fragile-X syndrome and myotonic dystrophy (235) . It is unknown whether the same mutational mechanism might involve the Brn-2 gene. A polyglutamine tractbinding protein, PQBP-1, capable of binding to the polyglutamine tract of Brn-2 and other such tracts of triplet repeat disease, has been identified (236) . While the function of this novel protein is unknown, it is known to be localized in the nucleus and capable of interfering with transactivation by Brn-2.
The N-terminal sequences of POU factors can also mediate repression, including regions from the N terminus of Oct-2 (237-242). Oct-3 binds to the promoter of Rex-1, which encodes an acidic zinc finger protein expressed at high levels in embryonic stem cells (108) . Depending on the cellular environment, Oct-3 can either activate or repress the promoter, with distinct domains within the N terminus being responsible for repression and activation.
Transactivation and chromatin.
Gene expression is influenced by chromatin structure (243) . Histones are regulated by acetylation of lysines in their N-terminal tails, allowing changes in histone conformation generally associated with increased access of DNA-binding proteins to promoters. In contrast, histone deacetylation is coupled to transcriptionally silent chromosomal domains. Many transcriptional coactivators possess intrinsic histone acetylation activity that is targeted to specific genes through interactions with DNAbinding proteins. Repressors, on the other hand, can recruit deacetylating enzymes to promoters, either directly or via the corepressor mSin3 (244, 245) .
N-CoR, originally identified as a nuclear receptor corepressor (246), has been reported to bind to the homeodomain of Pit-1 and actively suppresses transactivation by Pit-1. This suppression is dependent on mSin3, SAP30, and histone deacetylase (153, 247) . N-CoR may be limiting under certain conditions, and its binding to other transcription factors, such as nuclear hormone receptors, may indirectly activate transcription by Pit-1. The Pit-1 POU domain also associates with the coactivator complex consisting of CBP/p300 and P/CAF, both of which possess histone acetylase activity (152, 153) (Fig. 3) . Thus, the transcriptional activity of Pit-1 may be mediated by the competing binding of complexes responsible for either acetylation or deacetylation, resulting in activation or repression (Fig. 3) .
Conclusion.
Ultimately, it is likely that POU domain factors mediate their transcriptional activation by a combinatorial mechanism involving the N-and C-terminally located transactivation domains and coactivators/corepressors that interact with the POU domain (Fig. 3) . Since the involved coregulators participate in gene activation by many different transactivators, it is likely that the unique transactivation domains of POU domain factors provide specificity to the activation (228).
III. Development of the HypothalamoPituitary Region
The mature pituitary gland is composed of three distinct anatomical and functional entities (Fig. 4) (139, 248 -250): 1) the anterior lobe with five major hormone-producing cell types that respond to neuropeptides released from hypothalamic nuclei carried to the anterior pituitary gland via the portal circulatory system; 2) the posterior lobe containing specialized astroglia referred to as pituicytes, and magnocellular neuronal axons projecting from hypothalamic nuclei, releasing vasopressin and oxytocin (OT); and 3) the intermediate lobe containing melanotropes and endorphinsecreting cells (Fig. 4) .
The hypothalamus and the anterior pituitary gland develop from distinct regions of the most anterior part of ectoderm primordia (251) . Yet the development of these two organs is highly coordinated with neuronal projection arriving in the median eminence and the posterior pituitary gland at about the same time as these neurons start producing neuropeptides and receptors for these peptides become expressed in the anterior pituitary gland. Classical embryological experiments have suggested that the development of the anterior pituitary gland is dependent on inductive signals from the diencephalon (252) (253) (254) (255) .
Most of the hypothalamus appears to arise from the neuroepithelium ventral to the hypothalamic sulcus while the preoptic region arises rostral to the optic sulcus (256) . During development of the hypothalamus, between embryonic days 11 and 18 (e11 and e18) in the rat, periventricular neurosecretory cells become organized into several nuclei. These include the paraventricular (PVH), supraoptic (SO), arcuate, and periventricular nuclei (PVN). Development of the hypothalamus appears to progress in an outside-in gradient with the late-arising neurosecretory cell types occupying the most medial or periventricular zone of the hypothalamus. For descriptive purposes, four rostrocaudal levels of the hypothalamus can be described: preoptic, anterior, tuberal, and mammillary.
Within the hypothalamus, two distinct neurosecretory systems are organized (Fig. 5) (256) . One system is composed of magnocellular neurons that project axons directly into the posterior lobe of the pituitary gland (Fig. 5) . The magnocellular neuronal system includes neurons of the PVH and SON that synthesize OT and vasopressin (VP) and release these peptides into the posterior lobe of the pituitary gland. The second system is composed of parvocellular neurons that synthesize neuropeptides released into the pituitary portal circulation for regulation of the anterior pituitary gland (Fig.  5) . In addition to the magnocellular neurons, the PVH also harbors parvocellular neurons that synthesize, among other neuropeptides, CRH and TRH for regulating the ACTH/ adrenal axis and the TSH/thyroid axis, respectively. In the 
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POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEManterior periventricular and arcuate nuclei are parvocellular neurons that provide dopaminergic control of lactotrophs, and somatostatin/GRH control of somatotrophs. GnRH neurons originate in the olfactory placode and migrate during embryonic development to the hypothalamus (257) . GnRH is synthesized in scattered neurons throughout the hypothalamus, especially in preoptic hypothalamic neurons. It is involved in the initiation of puberty and regulation of FSH and LH synthesis in the anterior pituitary gland and thereby regulates reproduction. The anterior pituitary gland originates from an invagination in the oral ectoderm, referred to as Rathke's pouch (Fig. 6 ). When this oral ectoderm makes contact with the overlying neuroectoderm, around e9 in the mouse, a cascade of signaling events is initiated that ultimately lead to the generation of the anterior and intermediate lobes of the pituitary gland containing six distinct hormone-producing cells by e17.5 (139, 258). These cell types are corticotropes secreting ACTH, melanotropes secreting MSH, gonadotropes secreting LH and FSH, thyrotropes secreting TSH, somatotropes secreting GH, and lactotropes secreting PRL.
These cell types form in a spatial-specific manner earlier in mouse pituitary ontogenesis, around e10.5-14.5, during a period of active cell proliferation (Fig. 6 ). Thyrotropes and gonadotropes are most ventral and somatotropes and lactotropes reside in a dorsal position (139, 258) (Fig. 6 ). During this stage of pituitary organogenesis, at e15, corticotropes are distributed throughout the anterior pituitary gland (258 -260) . The spatial restricted organization of thyrotropes, gonadotropes, somatotropes, and lactotropes may be regulated by gradients of signaling molecules, including sonic hedgehog, bone morphogenic proteins (BMPs), FGFs, and Wnts, which in turn create overlapping spatial gradients of transcription factors (Fig. 6) . Thus, the transcription factors Nkx3.1, Six3, and Prop1 are expressed predominantly dorsally; Isl1, Brn-4, P-Frk, SF-1, and GATA-2 are expressed predominantly ventrally; and Pit-1 is expressed in an intermediary location, the site where lactotropes and somatotropes initially appear (248, 249) .
BMP4 signaling from the ventral diencephalon seems to be important for the early formation of the Rathke's pouch and seems to be linked to the induction of the transcription factor Isl1 (261). Later, FGF8 released from the ventral diencephalon and BMP2 released from mesenchymal cells ventral to the pouch and within the pouch seem to be important for patterning and cell proliferation (261) (262) (263) . Embryological studies in the rat suggest that the programs required for specification of all hormone-producing cell types is completed as Rathke's pouch closes (around e12 in the mouse).
Concurrent with the appearance of the anterior and intermediate lobes of the pituitary gland, formed from the ventral and dorsal aspects of Rathke's pouch, respectively, the posterior gland develops from neural ectoderm (Fig. 6 ).
IV. Expression and Function of POU Domain Factors in the Neuroendocrine System
A. Pit-1
Pit-1 proteins.
The Pit-1 gene encodes a 33-kDa protein composed of an 80-amino acid N terminus that functions as a transactivation domain and a C-terminally located POU FIG. 6 . A model describing pituitary gland development in the mouse. At e6.5 a part of the anterior ectoderm is already specified to form the hypothalamus and pituitary gland (not shown). At e10 the rudimentary Rathke's pouch is marked by expression of the LIM homedomain factor, Plim (Lhx3), within a larger region of Pitx-1-expressing cells in the oral ectoderm. Presumably, these transcription factors are responding to signals, including Shh, which is excluded from Rathke's pouch, and Wnt5a, BMP-4, and FGF-8 released from the diencephalon. Later, around e11, these signals set up a spatial pattern of transcription factor expression as indicated. As development proceeds, the appearance of hormone-expressing cells appears in a temporal-and spatial-specific manner that corresponds to the pattern of transcription factor expression. The first hormone-producing cells to appear, around e12, are the Pit-1-independent rostral tip thyrotropes (Tr) and corticotropes (C). Later, around e15, gonadotropes (G) and caudomedial thyrotropes (T) appear in a ventral location, and somatotropes (S) and lactotropes (L) appear more dorsally in a caudomedial location. At that stage, corticotropes are widely distributed in the anterior pituitary gland. Somatotropes, lactotropes, and caudomedial thyrotropes form in a location that corresponds to the expression domain of Pit-1. For illustrative purposes the patterns of hormone-producing cells are shown as strictly demarcated segments, but in reality there are no strict boundaries in the developing gland. Later, in the adult anterior pituitary gland, hormone-producing cells are intermixed. 264) . The N-terminal domain of Pit-1 is rich in hydroxylated amino acids (serines and threonines) and contains tyrosine residues that seem to be critical for transactivation function. Depending on the DNA site, Pit-1 can either bind as a monomer or dimer, which allows selective use of a tyrosine-dependent synergy domain in its N terminus (234) . Several alternatively spliced isoforms of Pit-1 have been described (81, [265] [266] [267] [268] . These include Pit-1␤, an isoform containing a 26-amino acid insertion, which is conserved among mammals, in position 48 of the N-terminal transactivation domain (265, 266, 269) . While Pit-1␤ is expressed at levels that are 7-to 8-fold lower than that of Pit-1, it has been shown in transient transfection assays that the Pit-1␤ isoform has distinct properties from Pit-1 (266, 270, 271) . Another isoform is Pit-1T, which contains a 14-amino acid insertion at the same location and may play a specific role in TSH␤ stimulation (268, 272) .
As previously described, Pit-1 can also be regulated at a posttranscriptional level. For instance, phosphorylation is reported to lead to decreased or increased DNA binding depending on the DNA-binding site (126, 128) . Activin leads to increased Pit-1 phosphorylation that not only decreases DNA binding, but also decreases the stability of Pit-1 (273).
Regulation of terminal differentiation. Ontogenic analyses
showed that the initial expression of Pit-1 in the caudomedial region of the pituitary gland at e14.5 in the mouse correlated both temporally and spatially with the subsequent activation of the GH, PRL, and TSH␤ genes (139, 274) (Fig. 6 ). Throughout development and in the adult, Pit-1 expression continues in somatotropes, lactotropes, and thyrotropes (Fig. 6) . Consistent with a role for Pit-1 in these cell types was the observation that the developmental-specific gene regulatory regions of the GH, PRL, and TSH␤ genes contain AT-rich elements to which Pit-1 binds and which mediate Pit-1-stimulated activation in transient transfection assays (71, 275, 276) . Subsequent analyses of the Pit-1-deficient Snell and Jackson dwarf mice suggested that these in vitro findings are of biological importance because, with the exception of TSH expression in Pit-1-independent rostral tip thyrotropes (72), activation of the GH, PRL, and TSH␤ genes fails in Pit-1-mutated mice (27) (Fig. 4) .
In addition to regulating target genes by binding to regulatory regions in close proximity to promoter regions, there are data implicating Pit-1 in regulating locus control regions (LCRs). The human pituitary GH (GH-N) gene contains Pit-1, Zn-15, and Sp1 binding sites in the first 140 bp upstream of the transcription start site. This region, however, is not sufficient for efficient expression in transgenic mice (277) and an LCR appears to be required for efficient and consistent expression of the hGH-N gene. LCRs, which mediate an efficient and position-independent expression of associated genes, are thought to perform their function by establishing open chromosomal domains as well as by acting as enhancers. Two pituitary-specific DNAse-hypersensitive sites were found in a 1.6-kb region located approximately 15 kb upstream of the transcription initiation site (277) and within this region enhancer activity was localized to a 404-bp region (278). This region contains three A/T-rich Pit-1-binding sites that seem to be important for the activity of this LCR in transgenic mice, suggesting that Pit-1 is involved in the enhancer activity of the GH LCR, consistent with a chromatinmediated developmental role for Pit-1 (279, 280). Interestingly, the A/T-rich Pit-1-binding sites bear some similarity to nuclear matrix anchorage sites (281), but it has been demonstrated that the POU-specific domain of Pit-1 contains information for targeting to the nuclear matrix (282).
Regulation of cell proliferation.
In addition to regulating expression of the terminal differentiation marker genes GH, PRL, and TSH␤, Pit-1 stimulates cell proliferation of pituitary cells, as evidenced in the Snell and Jackson dwarf mice, which are characterized by marked failure in the expansion of somatotropes, lactotropes, and thyrotropes (27) . In addition, microinjection of Pit-1 antisense sequences resulted in decreased cell proliferation of GC somotatroph cells (283). Recent findings have suggested three mechanisms involved in Pit-1-induced expansion of pituitary cells. First, experiments with adenovirus suggest that Pit-1 can directly regulate DNA replication in vitro (215) . Second, Pit-1 may directly regulate IE genes involved in cell-cycle initiation, such as c-fos (284). It has been shown that Pit-1 expression in PC12 cells, which do not normally express Pit-1, leads to increased c-fos expression. In addition, decrease of Pit-1 protein levels, by means of an antisense strategy, leads to decreased cAMPinduced c-fos promoter activity in pituitary cell lines. Finally, Pit-1 is required for expression of the GHRH receptor, which acts to stimulate proliferation of somatotrophs (74, 75, 285, 286). However, the ontogeny of GHRH receptor mRNA expression, which is highest at 19.5 in the rat with subsequent decrease until postnatal day 12, does not correlate with that of Pit-1, indicating that other factors, in addition to Pit-1, are important for GHRH receptor expression (287). Pit-1 binding sites have also been described in the TRH receptor gene regulatory region (78), suggesting a possible mechanism for Pit-1 regulation of proliferation of thyrotropes.
Regulation of Pit-1 gene expression.
The Pit-1 gene is located on chromosomes 3p11 and 16 in humans and mice, respectively. In the mouse, the Pit-1 gene is initially activated on e13.5-14 under control of a specific early enhancer that remains to be precisely characterized, but appears to be located between -5.1 and -10.2 kb upstream of the start site (288). From e16.5, Pit-1 expression requires a different autoregulated distal enhancer, located 10 kb upstream of the Pit-1 start site (70, 288). The distal enhancer contains three functional Pit-1 binding sites, a vitamin D receptor-binding site, and an retinoic acid response element (RARE) that mediates a Pit-1-dependent RAR induction (70). In the Snell dwarf mouse, Pit-1 gene expression at e14.5 is initiated normally but is extinguished in the perinatal period, apparently due to failure of autoregulation (27) . The proximal promoter region of the Pit-1 gene also contains Pit-1 binding sites (68, 69). Mutations in the transcription factor gene Prop-1 in the Ames dwarf mouse lead to a failure in the initial activation of Pit-1 gene expression (289); this effect, however, may be indirect. The transcription factor GATA-2 may be responsible for re-
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Restriction and selective facilitation of Pit-1 action.
Pit-1 is expressed in three distinct cell types in the anterior pituitary gland, and in each of these cell types it seems to be required for the expression of the characteristic hormone-encoding gene (Fig. 4) . Therefore, there must be mechanisms in place that limit the function of Pit-1 to prevent it, for example, from activating the GH gene in thyrotropes. There are some data suggesting that sequences in the target genes mediate active repression in heterologous pituitary cells (290, 291). The abundance of evidence, however, suggests that a complex combinatorial code based on synergistic interactions with other transcription factors is responsible for cell-specific target gene activation by Pit-1. The GH promoter is synergistically regulated by Pit-1 and TR/RXR or RAR/RXR (136, 292), apparently based on protein-protein interaction where Pit-1 can interact strongly with RXR but also to a lesser extent with TR and RAR (135). The synergism between Pit-1 and TR depends, in part, on Pit-1 residues that when mutated have no effect on Pit-1 acting alone. Thus, while the synergism amplifies the intrinsic activity of Pit-1, there are also functions that are specific to synergistic activation (134). Other transcription factors that bind to the GH promoter are a zinc finger transcription factor, Zn-15, which is required for activation of the GH gene (293) and C/EBP␣ (294), both binding to and activating the rat GH promoter in a synergistic fashion with Pit-1.
The PRL gene promoter is regulated by estrogens only when it is bound both by Pit-1 and the ER, and this synergistic regulation depends on the intact AF-2 domain of ER (137, 139, 141, 295, 296). There is evidence for direct interaction between ER and Pit-1 that is estrogen dependent (140). The Pit-1/ER synergism is modulated by nuclear receptor coactivators with RIP140 inhibiting and SRC-1 and GRIP1 stimulating (295). In addition, there is strong synergism between Pit-1 and Pitx1 (143, 144) and Pitx2 (146) on the PRL promoter.
Members of the ETS family of transcription factors can bind to a composite Ets-1/Pit-1 binding site in the rat PRL promoter (148, [297] [298] [299] . Synergistic gene activation between Pit-1 and Ets-1 may be important for basal activity and in mediating signals from growth factors and the Ras/mitogenactivated protein kinase (MAPK) pathway to the PRL gene (297) (298) (299) . The synergistic gene activation correlates with direct Pit-1-Ets-1 protein-protein interaction; this interaction is specific and not observed with Ets-2 (148). In addition, ETS factors do not bind to or activate the GH promoter and are therefore good candidates for factors contributing to the combinatorial control that is specific for PRL gene expression (148).
ETS-2 repressor factor (ERF) contains an ETS DNA binding domain and a C-terminal repressor domain (300) . This factor can bind to the PRL promoter and inhibit its activity. In cell lines, overexpression of ERF blocks induction of PRL transcription by protein kinase A and acts in an additive manner with dopamine to suppress PRL promoter activity, suggesting that dopamine and ERF may function by complementary mechanisms to suppress PRL promoter activity. In addition, it can block the cooperative activation of PRL gene expression by Pit-1 and ETs-1. ERF seems to act by inhibiting Pit-1 binding to the PRL regulatory elements and could be responsible for cell-specific repression of the PRL gene.
Studies on the human TSH␤ promoter suggest that there are functional interactions between Pit-1 and AP-1, with both factors binding to DNA, resulting in synergistic transcriptional regulation (301) . The activity of the transcription factor GATA-2, which appears to be required for the formation of both thyrotrope and gonadotrope cell types, can be modulated by Pit-1 (150, 151) . The presence of Pit-1 represses the gonadotrope phenotype via direct interactions with GATA-2, inhibiting its binding to cognate DNA sites important for generation of the gonadotrope phenotype (151) (Fig.  2A) . Pit-1 can thus inhibit promoters that contain GATA-2 binding sites and no Pit-1 binding sites, such as the gonadotrope-specific SF-1 promoter. In contrast, Pit-1 can also synergize with GATA-2 to promote the thyrotrope phenotype on promoters containing adjacent Pit-1 and GATA-2 sites, such as the thyrotrope-specific TSH␤ promoter (150, 151) ( Fig. 2A) .
The role of Pit-1 in hormonal regulation of target genes.
In addition to a role in regulating the appearance of cell types and expression of target genes during development, there is evidence that Pit-1 functions in the homeostatic hormonal regulation of gene expression in the anterior pituitary gland (302) . Experimental results suggest that Pit-1 participates in pathways for acute regulation of the GH, PRL, and TSH␤ genes.
GH gene regulation is stimulated by GHRH released into the tuberoinfundibular system and acting on the GHRH receptor located on somatotropes (303) . This G protein-coupled transmembrane receptor in turns acts by stimulating the production of cAMP and activating protein kinase A. While there are cAMP response elements (CREs) within the human GH promoter, experiments suggest that the protein kinase A signal is mediated by phosphorylation of CBP associating with and acting as a cofactor for Pit-1 (Fig. 3) .
Transcription of the PRL gene is regulated by dopamine, which acts by reducing intracellular cAMP concentration and lowering protein kinase A activity (304) . This response is unusual in that it does not appear to require CREB and CREs and instead may be mediated by the most proximal Pit-1-binding site of the rat PRL promoter. Mutagenesis of the three phosphoacceptor sites in the POU domain of Pit-1 showed that these are not required for hormonal regulation of PRL (127, 305) , suggesting that other proteins binding to this site or Pit-1-associated cofactors may be the substrate. Recently it was shown that Pit-1 and CBP synergistically regulate the PRL promoter, suggesting that association of CBP with Pit-1 may be responsible for cAMP regulation of the PRL gene (152) (Fig. 3) . It has also been shown that the cAMP response is enhanced by Oct-1 and the Pit-1␤ isoform (306) , suggesting that Oct-1 can act as a protein kinase A signaling cofactor. TRH, which is known to regulate PRL gene transcription, can stimulate PRL reporter plasmids in GH3 cells, apparently also via Pit-1 interacting with its binding sites in the PRL promoter (307, 308) .
Glucocorticoids mediate negative regulation of the human 
B. Oct-1
Oct-1 is ubiquitously expressed (309) and encodes a 100-kDa protein that has been implicated in the cell cycle-regulated expression of histone H2B (86) and in the ubiquitous expression of small nuclear RNA genes (84, 85). Based on these data, and the fact that Oct-1 can stimulate DNA replication (212, 310, 311) , it has been suggested that Oct-1 may play an important role in regulating cell proliferation. However, there is also a large amount of data suggesting that Oct-1 may play roles in regulating expression of cellular genes not associated with cellular proliferation. No knockout study of Oct-1 has been published.
Oct-1 in GnRH gene regulation.
Studies in the brain have suggested that Oct-1 is not highly expressed in neurons, especially nondividing mature neurons (312) , and is mostly found in glial cells (313) . However, there is evidence suggesting that Oct-1 may be directly involved in neuroendocrine gene regulation. Based on data from work with the hypothalamic cell line GT1-7, a model for GnRH-expressing neurons, the rat GnRH gene contains two regulatory regions: an evolutionary conserved proximal promoter region located between-170 and -1, and a 300-bp distal enhancer located approximately 1.7 kb upstream of the start site (29, 314) . The proximal promoter of the rat GnRH gene, which is critical for regulated expression of the GnRH gene by protein kinase C (29, 314) and progesterone (315) , is bound by several nuclear factors in the GT1-7 cell line (29) . In addition, this region contains at least two octamer-binding elements that are critical for transcription directed by the GnRH promoter in GT1-7 cells (29) . Two octamer sites are also found in the rat GnRH neuron-specific enhancer located 1.7 kb upstream of the promoter, and the activity of the enhancer is critically dependent on Oct-1 binding to these sites (28) . These data suggest that Oct-1 plays critical roles in regulation of GnRH transcription, by interacting with both enhancer and proximal promoter sequences, perhaps through homotypic interactions between Oct-1 bound to the enhancer and the promoter (28, 29) .
In the GT1-7 cell line, GnRH gene expression is repressed by the NO/cGMP signal transduction pathway (316) . This repression, which is mediated by the 300-bp distal enhancer, is obliterated when either an Oct-1 or a C/EBP binding site is mutated, suggesting that these factors play a role in the NO/cGMP pathway (317) . Consistent with this observation are experiments showing that NO analogs increase Oct-1 binding to octamer sites in GT1-7 cells (317). However, this effect of NO on Oct-1 binding may be cell-specific because in cultured vascular smooth muscle cells, NO inhibits Oct-1 DNA binding (318) . Such cell-specific effects of NO might be due to differential activation of signal transduction pathways in different cell types.
As previously described, experiments with the mouse GnRH promoter in the GT1-7 cell line suggest that GR can confer negative regulation on this promoter by associating with Oct-1 bound to one of the octamer elements (158, 319, 320). Apparently, this particular Oct-1 binding site imposes conformational changes that allow docking of GR to Oct-1 and repression of transcription (158).
Oct-1 in vasoactive intestinal peptide (VIP) gene regulation.
Oct-1 has also been implicated in regulation of VIP, which is widely distributed throughout the central and peripheral nervous system, including the hypothalamus and anterior pituitary gland (321, 322) . VIP can function as a neuromodulator, growth regulator, and neuroendocrine releasing factor. Experiments using subclones from the SK-N-SH neuroblastoma cell line to study the VIP promoter have identified an upstream tissue-specific element (TSE), located between -4.6 and -4.0 from the start site in addition to a proximal promoter element containing a CRE. The 425-bp TSE contains two octamer sites, similar to those found in the GnRH neuronal-specific enhancer, both of which are important for expression (30) . Both elements bound Oct-1 with the upstream element also binding Oct-2 in neuroblastoma cell extracts.
Oct-1 and TSH␤ gene silencing. Oct-1 has been implicated in silencing of the hTSH␤ gene in heterologous cells (291). Kim et al. localized an AT-rich region between -128 and -480 bp upstream of the start site. This element was bound by
Oct-1 in multiple locations, and silencing was mediated by the alanine-rich C-terminal domain of Oct-1. Oct-1, again acting through multiple binding sites, has also been implicated in silencing of the 3␣-hydroxysteroid/dihydrodiol dehydrogenase gene (323) . In addition, a silencer in the B cellspecific B29 (Ig␤) gene is an AT-rich region shown to bind Oct-1 and Oct-2 (324). Together, these studies and the fact that such AT-rich regions may serve as nuclear matrix attachment sites suggest that Oct-1 may have a general role in gene silencing. Consistent with this idea are observations that a significant amount of Oct-1 is found in the nuclear matrix fraction of nuclei (325, 326) .
C. Oct-2
Oct-2 encodes a 60-kDa protein, preferentially expressed in B lymphocytes, especially in the most mature cell types, as well as in the developing and adult nervous system (313, 327, 328) . In contrast to the widespread embryonic nervous system expression, Oct-2 is confined to specific areas in the adult, which include the suprachiasmatic and medial mammillary nuclei, hippocampus, olfactory tract, and the olfactory bulb (313) . Oct-2 proteins are present in both neuronal and oligodendroglial cells, but are more abundant in glial cells (313) . At least eight alternatively spliced mRNAs have been detected (329) , and there is evidence that the different splice variants, which are differentially expressed to a certain extent, may have different functions (327, 330) . In addition to the most predominant form, Oct-2A, two of the splice variants, Oct-2.5 and mini-Oct, are expressed at high levels in neural tissue (327) . Oct-2 has also been detected in intestine, testes, and kidney (313).
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POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEM1. Oct-2 gene-deleted mice. Oct-2 gene-deleted mice develop normally, including B cell development, but show an abnormal function of mature B lymphocytes with defective immunoglobin secretion in response to polyclonal antigens (331, 332) . These mice die within hours of birth, and while no gross structural abnormalities within the nervous system have been described (333) , it has been suggested that the cause of death may be abnormalities in the nervous system (332).
Oct-2 in GnRH regulation.
Other experiments have implicated Oct-2 in the regulation of GnRH gene expression and the onset of puberty (31) . While transsynaptic regulation of GnRH neurons is clearly important for the onset of puberty and regulation of reproduction, there is also evidence for GnRH neural regulation by astroglial cells within the hypothalamus. Lesions of the anterior hypothalamus lead to precocious puberty apparently caused by increased expression of TGF␣ by astrocytes formed in response to the lesion. TGF␣ is involved in stimulatory control of GnRH secretion and mimics some of the events in normal puberty. It has been demonstrated that in both lesion-induced puberty and normal puberty there is increased expression of Oct-2a and Oct-2c in the hypothalamus. Both Oct-2 forms can transactivate the TGF␣ gene promoter, and inhibition of Oct-2 synthesis with antisense technology reduces TGF␣ expression and the onset of puberty. These results suggest that the Oct-2 gene is an important component of a glia-to-neuron signal pathway leading to the onset of female puberty in mammals (31) . Since Oct-2 (Ϫ/Ϫ) mice die around the time of birth, a more rigorous testing of this hypothesis will require the use of a tissue-specific Oct-2 knockout.
D. Overview of expression of Brn-1, Brn-2, Brn-4, and Tst-1 in the neuroendocrine system
Several studies have described the expression patterns of class III POU factors (97, 256, 328, 334 -336) . At e10 to e11, Brn-1, Brn-2, and Brn-4 are expressed widely in the nervous system, including in the primordium of the endocrine hypothalamus adjacent to the third ventricle (328) . By e14, four separate rostrocaudally arranged areas (corresponding to the preoptic, anterior, ventromedial, and mammillary nuclei) of the hypothalamus are labeled with Brn-2 and Brn-1 (256) . At that time, both Brn-2 and Brn-4, but not Brn-1, are colocalized in the region of the developing PVH and SON and Brn-4 expression extends ventrally to potential precursors of the anterior hypothalamus. Brn-1-expressing cells are located immediately dorsolaterally in the presumptive zona incerta and in a dorsoventral stripe lateral to Brn-4-expressing cells. In contrast to the nearly identical widespread expression pattern of Brn-1 and Brn-2 in the developing nervous system, Tst-1 has restricted expression in the developing embryo, but shows dense hybridization signal in the mammillary region at e13. Tst-1 exhibits a much more widespread expression pattern in the adult (256) but is excluded from the hypothalamus.
Both Brn-2 and Brn-4 are expressed at high levels in the PVH and SON of the mature hypothalamus (37, 38, 328, 334, 335) . These nuclei contain the parvocellular neurons that synthesize high levels of CRH and the magnocellular neurons that synthesize arginine vasopressin (AVP) and OT (Fig.  5) . Double labeling studies show that Brn-2 is coexpressed with each of these neuropeptides, but not in a significant number of parvocellular neurons that produce TRH (38) . Double labeling experiments show that Brn-4 is not expressed in OT containing neurons of the PVN and SON, but is present in the magnocellular neurons of the PVN and SON that contain dynorphin and vasopressin (335) . Brn-2 levels in the PVH in response to ether stress have been studied, and it was found that Brn-2 levels were unchanged (337) .
The early neuronal expression of Brn-2, Brn-1, and Brn-4 has suggested a role for these factors in early neurogenesis (50, 328). Multipotential stem cells in the central nervous system are characterized by the expression of the intermediate filament protein nestin and the brain fatty acid binding protein (B-FABP). Regulatory regions of both genes, mapped in transgenic mice, contain POU binding sites close to hormone response elements (HRE), both of which are essential for expression of these stem cell markers (338) . In the rat nestin gene, the POU site is recognized by the class III POU proteins Brn-1, Brn-2, Brn-4, and Tst-1 and is critical for general central nervous system (CNS) expression, whereas the HRE is required for full expression in the anterior CNS. In the B-FABP gene a composite POU/Pbx site is essential for neuroepithelial expression. This site can bind Pbx-1, Brn-1, and Brn-2 in CNS extracts, suggesting the possibility that expression of class III POU domain factors may define the stem cell state. Exit from the stem cell state is indeed characterized by changes in expression with many class III genes being turned off and Brn-5 turned on (50, 339). So far, gene deletion experiments of Brn-2, Brn-4, and Tst-1 have shown no early defects consistent with such a model, indicating that either class III factors do not play important roles in early neural development or that redundancy between different members has prevented an observable phenotype in mice deleted for single class III genes.
As described below, with the exception of Brn-1, knockout experiments for all individual members of the class III POU factors have been reported.
E. Brn-2
Deletion of the Brn-2 gene in mice has provided the best evidence for the involvement of class III POU domain factors in neuroendocrine development and function (37, 38) . Brn-2 (Ϫ/Ϫ) mice are born normally but exhibit a decrease in size and weight from postnatal day (p) 3. Most die before p6 and exhibit a marked decrease in brown adipose tissue, consistent with severe malnutrition. Analyses showed dramatic hypothalamic/posterior pituitary gland abnormalities, but no obvious defects outside the hypothalamus (Fig. 5) . Among the most striking findings was a complete lack of CRH expression in parvocellular neurons of the PVH. This effect was extremely site specific because CRH expression was normal in other regions of the brain. In addition, parvocellular neurons of the PVH that produce TRH, but do not express Brn-2, were not affected. Further, OT and AVP expression was absent from the magnocellular neurons of the PVH and SON, but AVP expression in the non-Brn-2-
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ANDERSEN AND ROSENFELD Vol. 22, No. 1 expressing cells of the suprachiasmatic nucleus was maintained normally, again indicating that the defects were cell specific (38) . Similarly, anterior periventricular neurons that produce somatostatin and arcuate neurons that produce GHRH, which do not normally express Brn-2, were not affected. The lack of abnormalities in cells of the hypothalamus that do not express Brn-2 suggests that the phenotype of the Brn-2 (Ϫ/Ϫ) mouse is due to cell-autonomous effects. By e19.5, a striking decrease in cellularity of the PVH and SON was also observed. The developing posterior pituitary gland in Brn-2 (Ϫ/Ϫ) mice appears to be normal until e16.5 when axonal projections from magnocellular neurons fail to make contact (37, 38) . By e19 Brn-2 (Ϫ/Ϫ) mice show complete loss of pituicytes and a fold of the intermediate lobe instead fills the space normally occupied by the posterior lobe of the pituitary gland. Therefore, Brn-2 appears to be essential for magnocellular neurons to invade the posterior pituitary gland structure. These axons are then required for the survival of the pituicytes of the posterior pituitary gland. Surprisingly, despite the lack of CRH and AVP, ACTH expression in the pituitary gland of Brn-2 (Ϫ/Ϫ) mice is normal, as are the adrenal glands. This finding may indicate that alternative mechanisms are involved in regulating the ACTH/cortisol axis in the mouse.
Thus, the Brn-2 gene is required for the terminal differentiation and survival of cell types that compose the magnocellular system and one of the parvocellular cell types that comprise the central control of the pituitary-adrenal axis (Fig.  5) . Detailed ontogenic analyses suggest that precursors for neurons of the PVH and SON die around e12.5 during migration (37) . While the Brn-2 (Ϫ/Ϫ) mice show a severe phenotype in the PVH and SO, no obvious abnormalities are observed in the vast majority of neurons where Brn-2 is expressed. It has been proposed that overlapping expression with other class III POU factors, such as Brn-1, may provide redundancy to Brn-2 function in some neurons. However, in the PVH and SO, Brn-4 is clearly incapable of compensating for the loss of Brn-2. A proof for a model proposing both overlapping and specific neuroendocrine functions for each of the class III POU factors will require the analyses of double and triple mouse mutants.
While no morphological changes were observed in Brn-2 heterozygous (ϩ/Ϫ) mice, these mice only expressed half the level of Brn-2 compared with wild-type mice. Intriguingly, this decrease in Brn-2 levels correlated with 50% reduction in the levels of AVP and OT in Brn-2 (ϩ/Ϫ) mice (37) . These results suggest that Brn-2 levels are limiting for the expression of AVP and OT and that in addition to a developmental function in the specification of AVP and OT-producing neurons, Brn-2 has a direct role in regulating the expression of these genes in the adult. Consistent with this notion, several elements capable of binding class III POU factors have been identified in the region -1,535 to -1,270 in the rat OT gene (340) . In addition, the 5Ј-region of the CRF gene contains Brn-2-binding sites (63), which seem to be responsible for the activation of the CRF promoter (38) . Further support for this model comes from experiments with the neuroblastoma cell line BE(2)-M17, where retinoic acid induces expression of CRF. Expression of Brn-2 antisense RNA abrogates this response, suggesting that Brn-2 acts in a pathway mediating retinoic acid-induced CRF expression in terminally differentiated neurons (341) .
The basic helix-loop-helix (bHLH)-PAS transcription factor SIM1 is expressed in three hypothalamic nuclei during development: the PVN, the SO, and the anterior periventricular nucleus. In SIM1 (Ϫ/Ϫ) mice, the hypothalamus is hypocellular and neurons expressing OT, vasopressin, TRH, ACTH, and somatostatin (SS) are absent from these nuclei (342) . Thus, the phenotype of SIM1 gene-deleted mice is overlapping but more severe than that of Brn-2 gene-deleted mice. Evidence suggests that SIM1 functions to maintain Brn-2 expression, and part of the observed phenotype may be due to loss of Brn-2 expression (342). The relationship between SIM1 and Brn-2 in the hypothalamus is therefore somewhat analogous to the relationship between Prop1 and Pit-1 in the anterior lobe of the pituitary gland.
F. Brn-4
Deletion of the Brn-4 gene in mice resulted in multiple developmental defects in the inner ear, causing deafness, but no detectable defects in the development or function of the central nervous system (343, 344) . The inner ear phenotype is consistent with the expression of Brn-4 in the otic vesicle and derived structures. The lack of phenotype in most neurons expressing Brn-4 suggests the possibility that related POU domain factors may function on Brn-4-responsive genes in the absence of functional Brn-4.
Brn-4, which is highly expressed in proglucagon-expressing cells of the pancreas, binds to the G1 promoter element of the proglucagon promoter, and in transient transfection experiments, Brn-4 appears to be a major regulator of proglucagon gene expression (107) . It is unclear whether neuronal expression of proglucagon is regulated by the same mechanisms. The biological relevance of these in vitro studies is unknown because analysis of pancreatic structure or function in Brn-4 (Ϫ/Ϫ) mice has yet to be presented. Brn-4 has also been implicated in the regulation of striatal D1A dopamine receptor gene transcription (106) .
G. Tst-1
In addition to the previously described neuronal expression in the hypothalamus, Tst-1 is prominently expressed in myelin-forming glia of the central and peripheral nervous system during a period of rapid cell division (97-99, 328, 345, 346) . In cultured Schwann cells where cAMP induces the expression of myelin-specific genes, Tst-1 gene expression is also induced, preceding the induction of myelin-specific markers (345) . In addition, Tst-1 is expressed in embryonic stem cells and in the developing nervous system (97) . Expression in the brain is prominent in certain areas of the telencephalon, mesencephalon, brain stem, cortex anlagen, and in the developing colliculi (97, 328).
Tst-1 gene-deleted mice.
Deletion of the Tst-1 gene in mice produces a severe defect in peripheral myelination by arresting Schwann cell maturation before axonal wrapping (347, 348) . Most neuronal development appears to progress normally except for the phrenic nucleus, which is disrupted,
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POU DOMAIN FACTORS IN THE NEUROENDOCRINE SYSTEMand neurons of the nucleus of the lateral olfactory tract, which mismigrate. Most Tst-1 (Ϫ/Ϫ) mice die soon after birth but the occasional survivor is severely runted, consistent with a possible undefined defect in neuroendocrine function.
2. Tst-1 in GnRH gene regulation. Tst-1 transcripts are found in the neuronal cell line GT1-7, which produces GnRH, and in a subset of GnRH neurons in the hypothalamus of prepubertal female rats. In vitro studies using transfected cell lines have shown that Tst-1 can repress the GnRH promoter, apparently by binding to three sites in the promoter (100).
Since neurons capable of synthesizing GnRH seem to fluctuate between GnRH positivity and negativity depending on the reproductive cycle, it has been proposed that Tst-1 can determine the ratio of phenotypically active and inactive GnRH neurons during postnatal life (100).
H. Oct-3
The Oct-3 gene is expressed in male and female primordial germ cells, unfertilized oocytes (but not spermatocytes), and embryonic stem cells of the preimplantation embryo (51, 53, 349). The Oct-3 protein is also found in totipotent and pluripotent cells of the inner cell mass of the pregastrulation embryo, but not in the trophoectoderm. Expression of Oct-3 is required for the formation of totipotent cells of the embryo since mutation of the Oct-3 gene in mice causes all cells of the embryo to acquire a trophoblastic cell fate (49).
Oct-3 is expressed in the early embryo with expression in the headfold ectoderm extinguished around e8.5, when neural induction occurs (349) , suggesting that its disappearance might be important for early neural induction (50). The embryonic carcinoma P19 cell model for neural induction is consistent with this idea. Treatment with RA, which produces a neuronal like phenotype, leads to down-regulation of Oct-3 while forced expression of Oct-3 in certain differentiated P19 cells specifically represses expression of Brn-2 and nestin. Together, these data suggest the possibility that POU domain factors may control the acquisition and loss of stem cell characteristics in the CNS (50). Oct-3 is not expressed in the hypothalamus or pituitary gland and is not likely to play later roles in the neuroendocrine system.
I. Brn-5 and RPF-1
Brn-5 exhibits widespread expression in neurons and tissues outside the nervous system (56 -58, 350, 351) . Within the hypothalamus, expression of Brn-5 is reported in the mammillary nucleus and ventral area (339) . Brn-5 is also expressed in the anterior pituitary gland (56). During development, predominant expression is found in postmitotic neurons and not in proliferating neuronal precursors, suggesting that Brn-5 may have a role in regulating the postmitotic fate of these cells (339) . In addition, ectopic expression of Brn-5 in dividing NG108 -15 cells, a neuroblastoma/ glioma hybrid cell line, reduces proliferating cell nuclear antigen (PCNA) mRNA levels and inhibits DNA synthesis, suggesting the possibility that Brn-5 may suppress continued cell proliferation (352) . No specific function has been proposed for Brn-5 in the neuroendocrine system and a knockout study has not been reported.
The second class VI POU factor, RPF-1, is expressed only within the CNS, where its expression is restricted to the medical habenulla, to a dispersed population of neurons in the dorsal hypothalamus, and to subsets of ganglion and amacrine cells in the retina (59). No specific function has been proposed for RPF-1 in the hypothalamus, and a knockout study has not been reported.
V. Relevance of POU Domain Factors to Diseases of the Neuroendocrine System
A. Pit-1 mutations as a cause of combined pituitary hormone deficiency in humans
Several Pit-1 gene mutations that result in combined pituitary hormone deficiency (CPHD) have been described in humans (353) (354) (355) (356) (Table 8) . Clinically, patients usually have serum GH and PRL levels that are below detection in standard assays, indicating loss of all secretory function in somatotropes and lactotropes. Initially, some patients have detectable TSH levels, but ultimately all patients develop secondary hypothyroidism (Fig. 4) . In other cases, a severe central hypothyroidism has been diagnosed at birth (357) . NMR studies have shown variable normal or small anterior pituitary glands.
From a genetic standpoint, these mutations fall into one of two general classes: autosomal recessive and dominant (353) (354) (355) (Table 8) . Those inherited in an autosomal recessive pattern are often, but not always, due to disruption of DNA binding of Pit-1. Examples include Arg172Stop, Glu250Stop, Ala158Pro, Arg143Gln, Phe135Cys, and Pro239Ser. These mutations are similar to the Pit-1 mutation in the Snell dwarf mouse where a tryptophan at residue 261 is replaced with (Fig. 7) , was described in two homozygous Dutch families with severe GH and PRL deficiency but mild hypothyroidism (358) . An NMR study showed normal size anterior pituitary glands in the two affected patients (358) . The Ala158Pro protein binds normally to cognate DNA sites but is transcriptionally inactive on the GH, PRL, and Pit-1 promoters. Apparently, this region of the Pit-1 molecule is crucial for transactivation, either directly or through recruitment of coactivators.
The homozygous Phe135Cys Pit-1 mutation was found in four of eight siblings born to healthy consanguineous parents. This mutation affects a hydrophobic region of the first helix of the POU-S domain. All four patients presented with complete GH deficiency, later developed central hypothyroidism, and were found to have undetectable PRL levels. One of the patients had a successful NMR study at age 18, which showed a hypoplastic pituitary (359) .
A homozygous Pit-1 mutation, Pro239Ser, is located at the beginning of the second ␣-helix of the POU-H domain, in a position that is strictly conserved among all POU proteins. The Pro239Ser protein has been reported to bind to DNA, but fails to activate the GH promoter. This mutation has been reported in seven individuals from three unrelated Middle Eastern families (360) .
An isolated case has been described in which a patient harbored compound heterozygous mutations (361) . One mutation, Arg172Stop (Fig. 7) , results in a protein lacking part of the POU-S and all of the POU-H domains, predicting a complete loss of function. The other mutation, Glu174Gly, affects the DNA-recognition helix of the POU-S domain. This protein is reported to have drastically decreased affinity for DNA (361) . The Arg172Stop mutation has also been described in a homozygous form (362) .
Other human Pit-1 mutations have been described, but not extensively characterized. These include a homozygous mutation, Arg143Gln (Fig. 7 ), found in a child of consanguineous parents. This mutation is located within the first helix of the POU-S domain and presumably disrupts a basic region important for DNA binding (363) . Glu250Stop (Fig. 7) has been described in a single homozygous patient and would delete the DNA-recognition helix of the POU-H domain of Pit-1, thus interfering with DNA binding (364) .
A heterozygous Arg271Trp mutation (Fig. 7) , found both in sporadic and familial cases, seems to be a common cause of Pit-1 dysfunction, with at least 11 cases reported in unrelated families of diverse ethnic backgrounds (357, 363, (365) (366) (367) (368) (369) . The Arg271Trp mutant protein, which is altered in the basic region of the DNA-recognition helix of the homeodomain, binds DNA with normal or increased affinity but fails to stimulate transcription from Pit-1-responsive promoters and acts as a dominant repressor of transcription (366) . One patient was described to have abnormal facial features with prominent forehead, marked midfacial hypoplasia with depressed nasal bridge, deep-set eyes, and a short nose with anteverted nostrils (365) . These changes, however, are probably not specific for Pit-1 mutations because similar facial features, sometimes found in GH deficiency of other etiology, become less prominent with GH therapy. Interestingly, within a family some individuals harboring the Arg271Trp mutation may be clinically normal, possibly due to preferential expression from the normal Pit-1 allele (367).
Other less well characterized dominant mutations include Pro14Leu and Pro24Leu, which are located within the transactivation domain of Pit-1 and found in heterozygous individuals (363, 370, 371) .
An unusual heterozygous mutation, Lys216Glu, was described in a single patient. This mutation has no effect on DNA binding nor does it directly interfere with GH or PRL gene expression. Instead it blocks RA induction of Pit-1 gene expression. Cohen et al. (372) suggest that this mutation interferes with RA-induced activation of the Pit-1 gene during a crucial period of development (372) . This mutation affects the C-terminal part of the linker between the POU-S and POU-H domains and therefore may disrupt important protein-protein interactions between Pit-1 and other transcription factors (372) .
The Prop1 (Prophet of Pit-1) gene acts upstream of Pit-1 in Thus, whereas the phenotypes resulting from mutations in the human Pit-1 gene seem to mirror quite well the phenotype of the Pit-1-mutated Snell dwarf mouse, mutations in the human Prop1 gene can lead to a phenotype distinct from the Prop1-mutated Ames dwarf mouse. This observation has been interpreted that, in contrast to human disease mutations, the Prop1 mutation in the Ames dwarf is a hypomorph, leading to a partial loss of function. Regardless of the explanation, these data suggest that in humans, the Prop1 gene plays a role in the differentiation of at least gonadotropes, in addition to acting upstream of Pit-1 in generating the Pit-1-dependent cell lineages.
B. Brn-4 mutations in humans
Brn-4 mutations have been described in humans where they cause an X-linked nonsyndromic mixed deafness disorder referred to as DFN3 (343, 375) . As in the Brn-4 (Ϫ/Ϫ) mouse, no metabolic changes have been reported in these individuals, but specific metabolic tests might be needed to detect subtle differences.
C. Potential implications for other diseases
1. Pituitary adenomas. Several studies on the expression of Pit-1 in pituitary tumors have been published, showing Pit-1 commonly expressed in GH-, PRL-, and TSH␤-secreting tumors (376 -384). No major abnormalities in the amount or form of Pit-1 transcripts have been observed in these tumors, and Pit-1 mRNA levels seem to be similar in somatotrope and lactotrope adenomas (382, 385). In addition, Pit-1 is expressed in many clinically nonfunctioning pituitary adenomas, but in most of those, mRNAs for GH, PRL, or TSH␤ were also found (381). Pit-1 transcripts have also been found in ACTH-secreting tumors, again with expression seeming to correlate with GH-, PRL-, or TSH␤-expressing cells found in these tumors (381). Since Pit-1 has been implicated in proliferation of certain pituitary cell types during development, it is reasonable to propose that Pit-1 is at least a component in the pathways leading to the formation of these tumors.
Tuberoinfundibular dopamine, acting through dopamine D2 receptors, tonically inhibits PRL synthesis and secretion from lactotropes. As previously described, the dopamine signal may ultimately be transmitted through Pit-1 action on the regulatory region of the PRL gene (386, 387). Female mice deleted for the dopamine D2 receptor develop lactotroph hyperplasia and prolactinomas. Male mice deleted for the dopamine D2 receptor develop prolactinomas without any accompanying hyperplasia. In each case, these adenomas showed both Pit-1 and ER expression, suggesting that Pit-1 may participate in the pathway ultimately leading to experimental prolactinomas (388). In humans there seems to be a correlation between D2 receptor mRNA and Pit-1 mRNA levels in prolactinomas (382, 389).
Activating mutations in the G protein ␣(S) subunit, the gsp oncogene, may be responsible for as many as 40% of somatotropinomas (389). In transient transfection assays, a constitutively active ␣(S) subunit stimulates expression from a reporter construct under the control of the proximal 200 bp of the Pit-1 promoter. Full induction seems to depend on Pit-1 and CREB, which both bind to this region (390). Thus the overactivity of protein kinase A in this system may increase Pit-1 levels. In addition, the constitutive activation of this pathway may directly stimulate target genes such as the GH and PRL promoters (391). As previously described, this action seems to be mediated through Pit-1 binding sites in the GH gene, perhaps by direct interaction of CBP with Pit-1 (153, 303).
While there is evidence implicating Pit-1 as a target of signaling pathways that lead to pituitary adenoma formation in humans and mice (392), no specific abnormalities in Pit-1 expression or function implying a more causative role have been associated with the genesis of human pituitary tumors. One could hypothesize that putative activating mutations of Pit-1 may contribute to hormone-secreting tumor formation. However, even if Pit-1 abnormalities do not cause tumor formation, understanding Pit-1 function may help in designing strategies to control the secretion and proliferation of pituitary tumors of the somatomammotrope lineage.
2. Developmental defects. Septo-optic dysplasias, characterized by optic nerve hypoplasias, pituitary gland hypoplasias, and other midline abnormalities of the CNS, such as absence of the corpus callosum and septum pellucidum, are most likely caused by mutations in genes that act earlier than POU domain factors in the development of the hypothalamic/pituitary axes. Indeed, at least some cases are caused by a mutation in the paired like homeobox gene, Rpx/Hesx1, which acts early in pituitary development (393, 394).
Hypothalamic disease.
It is clear that the hypothalamus is important for several symptoms and diseases that fall outside classic neuroendocrine disorders. These include psychiatric diseases such as depression (395) , disturbances in the biological clock (396) , and obesity and other eating disorders (397 
